Zakiyah Neily, Insani Widya N, Suwantika Auliya A, van der Schans Jurjen, Postma Maarten J
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Padjadjaran University, Bandung 40132, Indonesia.
Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Padjadjaran University, Bandung 40132, Indonesia.
Vaccines (Basel). 2020 Jul 30;8(3):426. doi: 10.3390/vaccines8030426.
Evidence on costs and health benefits of pneumococcal conjugate vaccine (PCV) for children in Asian countries is limited but growing. As a region with a considerably high burden of pneumococcal disease, it is prominent to have a comprehensive overview on the cost-effectiveness of implementing and adopting a PCV vaccination program. We conducted a systematic review from Pubmed and Embase to identify economic evaluation studies of PCV for children in Asian countries up to May 2020. Data extraction included specific characteristics of the study, input parameters, cost elements, cost-effectiveness results, and key drivers of uncertainty. The Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement was followed for this systematic review. The reporting quality of the included studies was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. After the screening process on both the title and abstract and full text of 518 records, a total of 25 studies fulfilled the inclusion criteria, and were included in the review. The majority of included studies demonstrates that PCV for children is cost-effective in most of the Asian region, and even cost-saving in some countries. Most of the included studies implemented cost utility analysis (CUA) using either quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Overall, the main drivers affecting the cost effectiveness were vaccine price, burden regarding pneumonia-related parameters, and the inclusion of herd effects. The children pneumococcal vaccination program appears to be a cost-effective intervention in Asia, and even cost-saving in certain conditions. Vaccine price, pneumonia-related disease burden, and the inclusion of the herd effect are observed as important key drivers in estimating cost-effectiveness in this region. Incorporating PCV in vaccination programs in this region was found to be highly favorable.
关于肺炎球菌结合疫苗(PCV)对亚洲国家儿童的成本和健康效益的证据有限,但正在增加。作为一个肺炎球菌疾病负担相当高的地区,全面概述实施和采用PCV疫苗接种计划的成本效益非常重要。我们从PubMed和Embase进行了系统综述,以确定截至2020年5月亚洲国家儿童PCV的经济评估研究。数据提取包括研究的具体特征、输入参数、成本要素、成本效益结果以及不确定性的关键驱动因素。本系统综述遵循系统评价和Meta分析的首选报告项目(PRISMA)声明。使用综合健康经济评估报告标准(CHEERS)声明评估纳入研究的报告质量。在对518条记录的标题、摘要和全文进行筛选后,共有25项研究符合纳入标准,并被纳入综述。大多数纳入研究表明,儿童PCV在亚洲大部分地区具有成本效益,在一些国家甚至节省成本。大多数纳入研究使用质量调整生命年(QALY)或伤残调整生命年(DALY)进行成本效用分析(CUA)。总体而言,影响成本效益的主要驱动因素是疫苗价格、与肺炎相关参数的负担以及群体效应的纳入。儿童肺炎球菌疫苗接种计划在亚洲似乎是一种具有成本效益的干预措施,在某些情况下甚至节省成本。疫苗价格、与肺炎相关的疾病负担以及群体效应的纳入被视为该地区估计成本效益的重要关键驱动因素。发现在该地区的疫苗接种计划中纳入PCV非常有利。